Vor Biopharma
Michelle Lin is currently serving as the Vice President of Preclinical and Translational Biology at Vor Bio. Michelle has also held various leadership roles in preclinical sciences and HSC biology at different companies including Vor Bio, CRISPR Therapeutics, and Boston Children's Hospital. Michelle has a strong background in research and development within the field of hematology, particularly in sickle cell disease and β-thalassemia programs. Prior to their industry experience, Michelle worked as a Postdoctoral Fellow at Boston Children's Hospital and as a Research Technician at Cornell University. Michelle holds a PhD in Pharmacology from Yale University and a Bachelor of Arts in Biological Sciences/Physiology from Cornell University.
This person is not in any teams